Mode
Text Size
Log in / Sign up
Phase 4 N=468 Randomized Double-blind Diagnostic

Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography

Coronary Artery Disease

Enrolled (actual)
468
Serious AEs
0.2%
Results posted
Dec 2015
Primary outcome: Primary: Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment — 92.1; 95.4; 94.6 Percentage of patients — p=0.05

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
iobitridol (Drug); iopromide (Drug); iomeprol (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Guerbet
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment
92.1; 95.4; 94.6 0.05
SECONDARY
Average Image Quality According to Off-site Reading
3.5; 3.5; 3.4 0.750
SECONDARY
Coronary Track Rate
10.9; 10.8; 11.1
SECONDARY
Average Signal Attenuation After IV Injection of Contrast
426.3; 449.8; 466.4 0.001 sig
SECONDARY
Average Signal-to-Noise Ratio (Average SNR)
16.2; 17.1; 17.6 0.109
SECONDARY
Average Contrast-to-noise Ratio (Average CNR)
14.4; 15.3; 15.8 0.09

Summary

The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability (quality and interpretability of images).

Eligibility Criteria

Inclusion Criteria

  • Male or female adult patient (having reached legal majority age)
  • Symptomatic patient suspected for coronary artery disease scheduled for a coronary CT angiography

Exclusion Criteria

  • Patient with a heart rate > 65 beats per minute (bpm) and contraindication or intolerance to b-blocker administration
  • Patient with arrhythmia or non-sinus rhythm
  • Patient with decompensated heart failure
  • Patient with evidence of ongoing or active clinical instability (suspected or known acute myocardial infarction, cardiac shock, acute pulmonary oedema)
  • Patient who has previously undergone coronary artery bypass graft
  • Patient who has previously undergone percutaneous transluminal coronary stent placement
  • Patient with artificial heart valve
  • Patient with known moderate to severe aortic stenosis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01255722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search